Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId
PublicationView,CA193461,10.1158/2767-9764.crc-23-0257,Cancer Res Commun,37921419,https://pubmed.ncbi.nlm.nih.gov/37921419,Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor-positive Breast Cancer,2023,,"Yu-Chen Cheng, Shayna Stein, Agostina Nardone, Weihan Liu, Wen Ma, Gabriella Cohen, Cristina Guarducci, Thomas O McDonald, Rinath Jeselsohn, Franziska Michor","Cyclin-dependent kinases 4/6 (CDK4/6) inhibitors such as palbociclib are approved for the treatment of metastatic estrogen receptor-positive (ER+) breast cancer in combination with endocrine therapies and significantly improve outcomes in patients with this disease. However, given the large number of possible pairwise drug combinations and administration schedules, it remains unclear which clinica(Read more on Pubmed)",Mathematical Modeling,Breast Adenocarcinoma,Not Applicable,Not Applicable,Open Access,37921419,7370764b-5444-469a-aaa5-0c355e6636b7,syn52499989
